Quotient Limited (NASDAQ:QTNT) insider D J. Paul E. Cowan sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, October 18th. The stock was sold at an average price of $4.64, for a total transaction of $464,000.00. Following the completion of the transaction, the insider now directly owns 26,666 shares in the company, valued at $123,730.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Quotient Limited (QTNT) opened at 5.21 on Friday. The firm’s 50-day moving average is $4.66 and its 200-day moving average is $5.86. Quotient Limited has a 52 week low of $3.22 and a 52 week high of $7.74. The stock’s market capitalization is $74.90 million.
Quotient Limited (NASDAQ:QTNT) last released its earnings results on Monday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.55). The company had revenue of $6.83 million for the quarter, compared to analyst estimates of $5.70 million. Quotient Limited had a negative net margin of 381.66% and a negative return on equity of 13,050.41%. On average, equities research analysts predict that Quotient Limited will post ($2.01) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Insider Selling: Quotient Limited (NASDAQ:QTNT) Insider Sells 100,000 Shares of Stock” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/28/quotient-limited-qtnt-insider-d-j-paul-e-cowan-sells-100000-shares.html.
Several equities analysts have recently weighed in on the stock. ValuEngine raised shares of Quotient Limited from a “strong sell” rating to a “sell” rating in a research note on Friday, June 30th. Zacks Investment Research raised shares of Quotient Limited from a “sell” rating to a “hold” rating in a research note on Wednesday, September 20th. Finally, BTIG Research reissued a “buy” rating and issued a $12.00 price target on shares of Quotient Limited in a research note on Thursday, August 31st.
A number of large investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System purchased a new position in Quotient Limited in the 2nd quarter valued at about $349,000. The Manufacturers Life Insurance Company purchased a new position in Quotient Limited in the 2nd quarter valued at about $177,000. Scholtz & Company LLC purchased a new position in Quotient Limited in the 2nd quarter valued at about $939,000. State Street Corp purchased a new position in Quotient Limited in the 2nd quarter valued at about $1,728,000. Finally, Goldman Sachs Group Inc. purchased a new position in Quotient Limited in the 2nd quarter valued at about $104,000. Institutional investors own 57.70% of the company’s stock.
About Quotient Limited
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
Receive News & Ratings for Quotient Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Limited and related companies with MarketBeat.com's FREE daily email newsletter.